Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Locally Advanced Lung Non-Small Cell Carcinoma

Locally Advanced Lung Non-Small Cell Carcinoma

15

Pipeline Programs↗

5

Active Trials↗

10

Companies Involved↗

Locally Advanced Lung Non-Small Cell Carcinoma is an emerging landscape with 15 programs across 10 companies. 9 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

6/100

Mech. Concentration

10/100

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical3

Sotorasib

Amgen

Trastuzumab Deruxtecan

AstraZeneca

Trastuzumab

Organon and Co

Phase 13

Papaverine

Western Galilee Hospital-Nahariya

Bevacizumab

Roche

Brigatinib

Takeda

Phase 2

No programs

Phase 39

Carboplatin

Avyxa

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Durvalumab

AstraZeneca

Etoposide

Avyxa

Nab-Paclitaxel

Bristol-Myers Squibb

Approved

No programs

Analysis

Modality Breakdown

73%

Small molecule

11 of 15 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

5

clinical trials

Recruiting4 · 80%

Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

Longitudinal Assessment of Cardiovascular Injury and Cardiac Fitness in LA-NSCLC Patients Receiving Model Based Personalized Chemoradiation - an Adaptive Cohort Registration Study

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT05010109·100 enrolled

A Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib Plus Trastuzumab Deruxtecan in Patients With Advanced Non-Small Cell Lung Cancer With a KRASG12C Mutation

Recruiting·National Cancer Institute (NCI)·Preclinical·NCT07012031·37 enrolled

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer

Recruiting·NRG Oncology·Phase 3·NCT05624996·474 enrolled

Phase Ib Study of Brigatinib Plus Bevacizumab in Patients With ALK-Rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy

Active, not recruiting·CCity of Hope Medical Center·Phase 1·NCT04227028·5 enrolled

A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer

Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT05136846·28 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)